BioSight
Companies
SELLAS Life Sciences Group, Inc. logo

SLS

NASDAQNEW YORK, NY
SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company developing cancer immunotherapies and small molecule inhibitors. The company's lead program is galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen currently in Phase 3 development for acute myeloid leukemia, and its secondary program is SLS009, a selective CDK9 inhibitor small molecule in clinical-stage development for oncology indications.

Price history not yet available for SLS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar